Partners Group to Buy Majority Stake in Biotech FairJourney Biologics
By Elena Vardon
Partners Group Holding said it will buy a majority stake in antibody research organization FairJourney Biologics.
The Swiss private-equity firm didn't disclose the size of the investment but said that GHO Capital Partners, who it is buying the stake from, will remain a minority stakeholder and that founder Antonio Parada will also keep a significant shareholding.
FairJourney Biologics partners with pharmaceutical and biotechnology companies to develop antibody-based therapies.
According to a report from the Financial Times on Sunday, the deal values FairJourney Biologics at around 900 million euros ($964.4 million).
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
July 01, 2024 02:31 ET (06:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks